Shots:
- Amgen has reported P-III (DeLLphi-304) trial data evaluating Imdelltra (tarlatamab-dlle) vs SoC CT (topotecan globally excl. Japan; lurbinectedin in the US, Canada, Australia, Singapore, Korea; & amrubicin in Japan) in SCLC pts who progressed on or after single line of Pt-based CT
- In the interim analysis, trial met its 1EP, with superior OS; full data to be presented at a future conference
- Imdelltra is an immunotherapy that targets DLL3 on cancer cells & CD3 on T cells, triggering the T cells to destroy DLL3-expressing SCLC cells
Ref: Amgen | Image: Amgen
Related News:- Amgen’s Uplizna Receives the US FDA’s Approval for Immunoglobulin G4-related Disease (IgG4-RD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
